Format

Send to

Choose Destination
See comment in PubMed Commons below
Biologics. 2010 Mar 24;4:51-60.

Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency.

Author information

1
Division of Hematology, University Children's Hospital, Zurich, Switzerland.

Abstract

Protein C is one of the major inhibitors of the coagulation system that downregulate thrombin generation. Severe congenital protein C deficiency leads to a hypercoagulability state that usually presents at birth with purpura fulminans and/or severe venous and arterial thrombosis. Recurrent thrombotic events are commonly seen. From the 1990's, several virus-inactivated human protein C concentrates have been developed. These concentrates currently constitute the therapy of choice for the treatment and prevention of clinical manifestations of severe congenital protein C deficiency. This review summarizes the available information on the use of human protein C concentrates in patients with severe congenital protein C deficiency.

KEYWORDS:

Congenital protein C deficiency; protein C concentrate; purpura fulminans

PMID:
20376174
PMCID:
PMC2846144
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center